PURPOSE: Multiple imaging techniques are nowadays available for clinical in-vivo visualization of @entity5 biology. FDG PET/CT identifies @entity5 metabolism, @entity519 PET @entity5 oxygenation and dynamic contrast-enhanced (DCE) CT characterizes vasculature and morphology. We explored the relationships among these biological features in @entity1 with @entity1149 ( @entity1149 ) at both the @entity1 level and the @entity5 subvolume level. METHODS: A group of 14 @entity1149 @entity1 from two ongoing clinical trials (NCT01024829 and NCT01210378) were scanned using FDG PET/CT, HX4 PET/CT and DCE CT prior to chemoradiotherapy. Standardized uptake values (SUV) in the primary @entity5 were calculated for the FDG and @entity519 HX4 PET/CT scans. For @entity519 imaging, the @entity519 volume, fraction and @entity5 -to-blood ratio (TBR) were also defined. Blood flow and blood volume were obtained from DCE CT imaging. A @entity5 subvolume analysis was used to quantify the spatial overlap between subvolumes. RESULTS: At the @entity1 level, negative correlations were observed between blood flow and the @entity519 parameters (TBR >1.2): @entity519 volume (-0.65, p   =   0.014), @entity519 fraction (-0.60, p   =   0.025) and TBR (-0.56, p   =   0.042). At the @entity5 subvolume level, @entity519 and metabolically active subvolumes showed an overlap of 53        36  %. Overlap between @entity519 sub-volumes and those with high blood flow and blood volume was smaller: 15        17  % and 28        28  %, respectively. Half of the @entity1 showed a spatial mismatch (overlap <5  %) between increased blood flow and @entity519 . CONCLUSION: The biological imaging features defined in @entity1149 showed large interpatient and intratumour variability. There was overlap between @entity519 and metabolically active subvolumes in the majority of @entity5 , there was spatial mismatch between regions with high blood flow and those with increased @entity519 .

Multiparametric imaging of @entity1 and @entity5 heterogeneity in @entity1149 : quantification of XXXX , metabolism and perfusion.

@entity5 :: ('MESH:D009369', 'Disease') :: ['visualizes tumour', 'increased tumour', 'tumours', 'tumour'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxic', 'hypoxia'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer', 'NSCLC tumours']
@entity5 :: (MESH:D009369,Disease) :: ['tumour hypoxia']
